Drug manufacturer Novo Nordisk’s blockbuster weight loss drug Wegovy is capable of reducing the risk of serious heart events in users, says a new study.
According to the research, weekly use of Wegovy helped slash the likelihood of major cardiovascular events by 20%.
With the new findings, Wegovy may receive increased insurance coverage nationwide.
“This is the first time that medication approved for chronic obesity management can be considered life saving,” said Northwestern University professor Dr. Robert Kushner.
